• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

加纳人和德国人之间司巴丁氧化的种族间差异。

Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans.

作者信息

Eichelbaum M, Woolhouse N M

出版信息

Eur J Clin Pharmacol. 1985;28(1):79-83. doi: 10.1007/BF00635712.

DOI:10.1007/BF00635712
PMID:3987789
Abstract

Sparteine oxidation, which exhibits genetic polymorphism in various Caucasian populations, was studied in 154 unrelated Ghanaian subjects. Mean total urinary recovery of sparteine and 2- and 5-dehydrosparteines (56.6 +/- 16.6% of the dose) was not different from Caucasians. In contrast to Caucasians, amongst whom 6.3 to 9% of the population are poor metabolizers (PM), no PM subject was observed in the Ghanaian population sample. The data appear to indicate allelic differences between Caucasians and Ghanaians in the gene encoding the synthesis of the P-450 isozyme involved in polymorphic sparteine oxidation.

摘要

在154名无亲缘关系的加纳受试者中研究了鹰爪豆碱氧化作用,该作用在不同白种人群体中表现出遗传多态性。鹰爪豆碱、2-脱氢鹰爪豆碱和5-脱氢鹰爪豆碱的尿中总回收率(占给药剂量的56.6±16.6%)与白种人无差异。与白种人不同,白种人群体中有6.3%至9%的人是慢代谢者(PM),而在加纳人群样本中未观察到慢代谢者。这些数据似乎表明,在编码参与多态性鹰爪豆碱氧化的P-450同工酶合成的基因中,白种人和加纳人之间存在等位基因差异。

相似文献

1
Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans.加纳人和德国人之间司巴丁氧化的种族间差异。
Eur J Clin Pharmacol. 1985;28(1):79-83. doi: 10.1007/BF00635712.
2
Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians.加纳人群中异喹胍/苯乙双胍与司巴丁氧化共调节控制的解离
Clin Pharmacol Ther. 1985 May;37(5):512-21. doi: 10.1038/clpt.1985.81.
3
Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians.加纳人、中国人和高加索人中三种CYP2D6探针底物与基因型的比较。
Pharmacogenetics. 1998 Aug;8(4):325-33. doi: 10.1097/00008571-199808000-00006.
4
Evidence for polymorphic oxidation of sparteine in Japanese subjects.日本受试者中司巴丁多态性氧化的证据。
Br J Clin Pharmacol. 1987 Apr;23(4):482-5. doi: 10.1111/j.1365-2125.1987.tb03080.x.
5
Sparteine oxidation polymorphism in Greenlanders living in Denmark.生活在丹麦的格陵兰人的鹰爪豆碱氧化多态性
Br J Clin Pharmacol. 1986 Oct;22(4):415-9. doi: 10.1111/j.1365-2125.1986.tb02911.x.
6
Absence of polymorphism of sparteine oxidation in the South African Venda.
Hum Exp Toxicol. 1991 May;10(3):175-8. doi: 10.1177/096032719101000304.
7
Sparteine oxidation polymorphism in Denmark.丹麦的鹰爪豆碱氧化多态性
Acta Pharmacol Toxicol (Copenh). 1985 Nov;57(5):357-60. doi: 10.1111/j.1600-0773.1985.tb00058.x.
8
Sparteine oxidation polymorphism: a family study.鹰爪豆碱氧化多态性:一项家族研究。
Br J Clin Pharmacol. 1986 Jun;21(6):661-7. doi: 10.1111/j.1365-2125.1986.tb05231.x.
9
The genetic polymorphism of sparteine metabolism.司巴丁代谢的基因多态性
Xenobiotica. 1986 May;16(5):465-81. doi: 10.3109/00498258609050252.
10
Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians.加纳人和高加索人中异喹胍羟基化多态性
Clin Pharmacol Ther. 1979 Nov;26(5):584-91. doi: 10.1002/cpt1979265584.

引用本文的文献

1
Prediction and visualization of CYP2D6 genotype-based phenotype using clustering algorithms.使用聚类算法对基于CYP2D6基因型的表型进行预测和可视化。
Transl Clin Pharmacol. 2017 Sep;25(3):147-152. doi: 10.12793/tcp.2017.25.3.147. Epub 2017 Sep 15.
2
Pharmacogenetics of antidepressants, mood stabilizers, and antipsychotics in diverse human populations.不同人群中抗抑郁药、心境稳定剂和抗精神病药物的药物遗传学
Discov Med. 2013 Sep;16(87):113-22.
3
Pharmacogenetics in Ghana: reviewing the evidence.加纳的药物遗传学:证据综述。

本文引用的文献

1
INSUFFICIENT PARAPHYDROXYLATION AS A CAUSE OF DIPHENYLHYDANTOIN TOXICITY.羟化不足作为苯妥英钠毒性的一个原因
Neurology. 1964 Jun;14:542-8. doi: 10.1212/wnl.14.6.542.
2
The polymorphic 4-hydroxylation of debrisoquine in a Saudi arab population.沙特阿拉伯人群中异喹胍的多态性4-羟化作用
Xenobiotica. 1980 Nov;10(11):819-25. doi: 10.3109/00498258009033812.
3
Debrisoquine hydroxylation capacity: problems of assessment in two populations.异喹胍羟基化能力:两个群体中的评估问题。
Ghana Med J. 2011 Jun;45(2):73-80. doi: 10.4314/gmj.v45i2.68932.
4
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.细胞色素P450 2D6:药理学、遗传学、生物化学概述及最新进展
Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):23-37. doi: 10.1007/s00210-003-0832-2. Epub 2003 Nov 15.
5
Pharmacokinetic evaluation of herbal remedies. Basic introduction, applicability, current status and regulatory needs.草药疗法的药代动力学评估。基本介绍、适用性、现状及监管需求。
Clin Pharmacokinet. 1997 Jun;32(6):427-36. doi: 10.2165/00003088-199732060-00001.
6
Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping.药物代谢中的多态性,包括抗抑郁药物:关于表型分析的评论
J Psychiatry Neurosci. 1994 Jan;19(1):30-44.
7
Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans.美国黑人中细胞色素P450 2D6氧化药物代谢缺陷表型患病率较低的遗传基础。
J Clin Invest. 1993 May;91(5):2150-4. doi: 10.1172/JCI116441.
8
Genetically determined sparteine oxidation polymorphism in a Polish population.
Eur J Clin Pharmacol. 1994;46(5):481-3. doi: 10.1007/BF00191917.
9
Sparteine oxidation polymorphism in Greenlanders living in Denmark.生活在丹麦的格陵兰人的鹰爪豆碱氧化多态性
Br J Clin Pharmacol. 1986 Oct;22(4):415-9. doi: 10.1111/j.1365-2125.1986.tb02911.x.
10
Sparteine oxidation is practically abolished in quinidine-treated patients.在接受奎尼丁治疗的患者中,鹰爪豆碱氧化实际上被消除了。
Br J Clin Pharmacol. 1986 Aug;22(2):194-7. doi: 10.1111/j.1365-2125.1986.tb05250.x.
Clin Pharmacol Ther. 1981 Feb;29(2):218-23. doi: 10.1038/clpt.1981.35.
4
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.对英国白人人群中异喹胍氧化遗传多态性的家系及群体研究。
J Med Genet. 1980 Apr;17(2):102-5. doi: 10.1136/jmg.17.2.102.
5
Deficient metabolism of debrisoquine and sparteine.异喹胍和鹰爪豆碱代谢缺陷。
Clin Pharmacol Ther. 1980 Apr;27(4):547-9. doi: 10.1038/clpt.1980.77.
6
[Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population].
Schweiz Med Wochenschr. 1982 Jul 24;112(30):1061-7.
7
In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine.人肝脏对司巴丁的体外代谢:地昔帕明的竞争性抑制作用。
Can J Physiol Pharmacol. 1982 Jan;60(1):102-5. doi: 10.1139/y82-017.
8
Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.鹰爪豆碱和异喹胍的多态性氧化:相关药物遗传学实体。
Clin Pharmacol Ther. 1982 Feb;31(2):184-6. doi: 10.1038/clpt.1982.29.
9
Sparteine metabolism in Canadian Caucasians.
Clin Pharmacol Ther. 1982 Jan;31(1):23-9. doi: 10.1038/clpt.1982.4.
10
Defective oxidation of drugs: pharmacokinetic and therapeutic implications.药物氧化缺陷:药代动力学及治疗学意义
Clin Pharmacokinet. 1982 Jan-Feb;7(1):1-22. doi: 10.2165/00003088-198207010-00001.